Please login to the form below
Biovitrum
This page shows the latest Biovitrum news and features for those working in and with pharma, biotech and healthcare.
Sanofi and Sobi’s efanesoctocog alfa granted FDA priority review for haemophilia A
Sanofi and Swedish Orphan Biovitrum's (Sobi) Biologics Licence Application (BLA) for efanesoctocog alfa (BIVV001) for the treatment of haemophilia A has been accepted by the US Food and Drug Administration
Latest news
-
Sanofi and Sobi announce positive phase 3 trial results for severe haemophilia A
Sanofi and Swedish Orphan Biovitrum (Sobi) have announced positive results from a phase 3 trial, showing once-weekly efanesoctocog alfa provided ‘clinically meaningful’ bleed protection for patients with severe haemophilia A.
-
Sobi set to spend up to $915m to acquire Dova Pharmaceuticals
Hopes to boost haematology franchise with lead drug Doptelet. Dova Pharmaceuticals is set to be acquired by Swedish Orphan Biovitrum AB (Sobi) for up to $915m, dependent on the regulatory approval
-
Sobi shows strong growth despite haemophilia competition
Looking to M&A for continued growth. Rare disease specialist Swedish Orphan Biovitrum (Sobi) has posted strong growth for the first quarter of the year, led by its haemophilia franchise.
-
US, EU regulators back rapid reviews of AZ’s RSV med
With MEDI8897, AZ and its partners for the drug – Sanofi and Swedish Orphan Biovitrum (Sobi) – have the opportunity to open up the RSV prevention market beyond high-risk patients, as its
-
FDA clears Sobi’s Gamifant for ‘hyper-inflammation’ disease
Approval adds to growing US portfolio. Swedish Orphan Biovitrum (Sobi) has the US approval it sought for Gamifant, an ultra-rare disease therapy it licensed from Novimmune for $452m a few
More from news
Approximately 5 fully matching, plus 19 partially matching documents found.
Latest Intelligence
-
A rare opportunity
Orphan Biovitrum) a company that, as its name suggests, is entirely dedicated to rare conditions.
-
Deal Watch table for July 2013
49. †Auxilium Pharmaceuticals/ Swedish Orphan Biovitrum. Development, supply and commercialisation. Xiapex (collagenase clostridium histolyticum) (approved).
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
Sobi poaches Pfizer’s Fredrick Wetterlundh
Swedish Orphan Biovitrum (Sobi) has appointed Fredrik Wetterlundh as head of human resources and will simultaneously be part of Sobi’s extended leadership team.
-
Mereo BioPharma appoints head of patient access and commercial planning
Most recently, Hughes-Wilson served on the executive leadership team as chief patient access officer and senior vice president access and external affairs at Swedish Orphan Biovitrum (Sobi), a speciality healthcare
-
Sobi appoints Norbert Oppitz SVP, speciality care
He joins the rare disease pharma firm from BSN Medical. Rare diseases healthcare company Swedish Orphan Biovitrum (Sobi) has appointed Norbert Oppitz as its senior vice president for its newly established
-
Bo Jesper Hansen to step down as chairman of Sobi
Biovitrum and Swedish Orphan International in 2010. ... He has also served as a member of several firms' board of directors, including Alere, Coloplast, Danisco, Lundbeck and Biovitrum.
-
GSK appoints rare diseases research head
Birgitte Volck moves to the company from Swedish Ophan Biovitrum. GlaxoSmithKline has appointed Birgitte Volck has its new head of rare diseases R&D. ... She will join GSK after working her six months notice at Swedish Ophan Biovitrum (Sobi), which she
More from appointments
Approximately 2 fully matching, plus 7 partially matching documents found.
Subscribe to our email news alerts
-
Pharmacovigilance Manager
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Technical Sales Representative
- Highly competitive salary
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- MHRA to introduce new UK clinical trials framework
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Virtual Patient Engagement Program: A Customer Story
- Putting Skin in the Game at AAD 2023
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- NHS England announces rare genetic disorder fast-tracking service
- NICE sees ‘promise’ in four UTI tests that could help in fight against AMR
- Connectome competitiveness
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Trust me, I’m from pharma
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- Pfizer and Astellas’ Xtandi shows promise in phase 3 prostate cancer study
- Sobi’s Kineret granted FDA Emergency Use Authorisation for COVID-19 related pneumonia
PMHub
Four Health
Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...
Latest intelligence
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
